Human Papillomavirus (HPV) Infection Vaccines Market Outlook, Research with Size, Growth, Key Players, Segments and Forecasts Analysis

HPV Infection Vaccines Market

   Human papillomavirus (HPV) is a group of 150 related viruses, 75 percent of which cause warts on the arms, chest, feet, and hands, and 25 percent of HPV types known as high-risk HPV cause genital cancer. Human papillomavirus testing is used to screen for a variety of cancers, including cervical cancer, vaginal cancer, vulvar cancer, and others. According to the Centers for Disease Control and Prevention (CDC), HPV infection is linked to 66 percent of cervical cancers, 79 percent of anal cancers, 55 percent of vaginal cancers, and 62 percent of oropharyngeal cancers in women in the United States. The human papillomavirus test has been approved by the FDA as a preliminary screening test for cervical cancer. Despite FDA approval, the test can only be used in conjunction with the Pap smear test – the gold standard test for cervical cancer screening.

  Conventional human papillomavirus testing employs molecular biology techniques such as radioactive isotope-labeled nucleic acid probes. The inability of these tests to detect all oncogenic and non-oncogenic HPV types is the most significant impediment to the Human Papillomavirus (HPV) Infection Vaccines Market. The introduction of new HPV screening techniques, such as the DNA hybridization signal amplification system, has created lucrative opportunities for manufacturers of human papillomavirus testing kits. New HPV testing techniques employ Southern blotting, polymerase chain reaction (PCR), and other techniques for HPV detection, species identification (genotyping), and viral load detection. For women over the age of 30, an HPV test is recommended.

  Due to the availability of clear guidelines for the use of the Human Papillomavirus (HPV) Infection Vaccines Market in cervical cancer screening, the cervical cancer segment is expected to contribute the largest share of the global human papillomavirus testing market. The global human papillomavirus testing market has been classified into hospitals, clinics, Diagnostic Centers, and Research Centers based on end-users. The hospital end-user segment is expected to contribute the most end-user revenue.

  The increasing prevalence of both diseases in emerging regions such as the Asia Pacific and Latin America is the primary driver of the global HPV and CMV therapeutics market. The ongoing cultural shift in these regions has contributed to an increase in the prevalence of sexually transmitted diseases, which is driving the market for HPV therapeutics. Developing regions present lucrative opportunities for manufacturers of both HPV and CMV therapeutics due to the rapid ongoing development of the healthcare sector. As a result, many leading market players are focusing their efforts on improving their performance in underdeveloped/developing economies.